Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin
| Autor: | Michael F. Lyons, K. Rajender Reddy, Brooke Huntley, Michael J. Ryan, John Santoro, Robert W. Sjogren, Maria H. Sjogren, Herbert L. Bonkovsky, Sima Faris-Young, C. Smith |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male Physiology Hepatitis C virus Population Interferon alpha-2 medicine.disease_cause Antiviral Agents Polyethylene Glycols chemistry.chemical_compound Pegylated interferon Ribavirin medicine Humans Interferon alfacon-1 education Fatigue Aged education.field_of_study business.industry Depression Gastroenterology virus diseases Interferon-alpha Hepatitis C Hepatitis C Chronic Middle Aged Viral Load medicine.disease Virology digestive system diseases Recombinant Proteins chemistry Interferon Type I Quality of Life Drug Therapy Combination Female Viral hepatitis business Viral load medicine.drug |
| Zdroj: | Digestive diseases and sciences. 52(6) |
| ISSN: | 0163-2116 |
| Popis: | Achieving an antiviral response at a reasonable cost is a challenge in the treatment of patients with chronic hepatitis C. A previous study indicated that consensus interferon with ribavirin had promising activity against hepatitis C virus (HCV) genotype 1. The objective of this study was to determine the virologic response with consensus interferon or pegylated interferon alpha-2b plus weight-ribavirin in patients chronically infected with HCV genotype 1. Intention-to-treat analysis showed response in 37% and 41% of subjects treated with consensus interferon/ribavirin or pegylated interferon/ribavirin, respectively, with response rates of 42% and 44% observed in analysis of the per-protocol population, not a significant difference. Tolerability of the two treatment regimens was similar. In conclusion, both treatment regimens were safe and gave a similar antiviral response. It is possible that if consensus interferon is administered daily rather than three times weekly, eradication of HCV could be achieved in a larger proportion of patients infected with HCV genotype 1. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink